Evuzamitide as SPECT/CT Imaging Agent for Diagnosis of Transthyretin Amyloidosis
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a single center, prospective cohort study that is evaluating the ability of
124I-evuzamitide PET scanning to: (1) identify extra-cardiac amyloid deposits in patients
with ATTRwt-CA and the Val122Ile variant; (2) to detect cardiac TTR amyloidosis in subjects
with heart failure, increased wall thickness but only grade 1 Tc99PYP scans who are not
currently diagnosed with ATTR-CA; and (3) to detect cardiac ATTR in allele carriers of TTR
variants (Phe64Leu, late onset Val30Met) that are associated with cardiac amyloidosis but
have PYP scans not diagnostic of ATTR-CM. If 124I-evuzamitide PET scanning is shown to be
valuable in any of these three cohorts, it would address critical unmet needs regarding the
diagnosis and extent of disease in ATTR-CM.
Consented eligible patients will undergo a single 124I-evuzamitide PET scan. Clinically
available demographic, clinical and phenotypic data that is collected as part of routine
clinical care will be used to characterize the type, severity, and stage of ATTR-CM.